<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986193</url>
  </required_header>
  <id_info>
    <org_study_id>Skejby 2008-1</org_study_id>
    <nct_id>NCT00986193</nct_id>
  </id_info>
  <brief_title>Transapical Transcatheter Treatment Versus Conventional Surgery in Patients With Native Aortic Valve Stenosis</brief_title>
  <official_title>Randomized Comparison of Transapical Transcatheter Treatment Versus Conventional Surgery in Patients With Native Aortic Valve Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomised comparison of apical stent valve treatment versus conventional&#xD;
      valve surgery in patients with severe aortic valve stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to compare the new established apical stent valve treatment with&#xD;
      conventional surgical intervention using biological valve prostheses in patients with severe&#xD;
      aortic valve stenosis.&#xD;
&#xD;
      The Edwards-SAPIENTM Transcatheter Heart Valve (Edwards Lifesciences, Irvine, CA) will be&#xD;
      used in the stent valve group. The Carpentier-Edwards-Perimount Heart Valve (Edwards&#xD;
      Lifesciences, Irvine, CA) will be recommended for the conventional surgery group.(Edwards&#xD;
      Lifesciences, Irvine, CA).&#xD;
&#xD;
      Heart centres in the Nordic region with experience (&gt;10 cases) in apical stent valve&#xD;
      treatment and in conventional surgical treatment of high risk patients with aortic valve&#xD;
      stenosis. The study will be initiated at Aarhus University Hospital, Skejby, Denmark.&#xD;
&#xD;
      Study hypothesis:&#xD;
&#xD;
      As compared to conventional aortic valve substitution in patients aged &gt;75 years, apical&#xD;
      stent valve treatment reduces the rates of death, cerebrovascular insult (CVI) and need of&#xD;
      dialysis for renal failure 1 month after the treatment.&#xD;
&#xD;
      Primary clinical end-point:&#xD;
&#xD;
      Combined end-point consisting of death, CVI and/or renal failure with need for haemodialysis,&#xD;
      1 month after index treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    By recommendation from the Data and safety monitoring board&#xD;
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death, CVI and/or renal failure requiring any dialysis</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic results, valve performance</measure>
    <time_frame>1 month with subseguent followup</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Conventional Aortic Valve Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insertion of a biological valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transapical Aortic Valve Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transapical implantation of an Edwards SAPIENtm valve</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transapical Aortic Valve Implantation</intervention_name>
    <description>Insertion of a stent valve using catheter-based technique through a mini thoracotomy</description>
    <arm_group_label>Transapical Aortic Valve Implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Aortic Valve Surgery</intervention_name>
    <description>Operation using heart-lung machine, with insertion of a biological artificial heart valve</description>
    <arm_group_label>Conventional Aortic Valve Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Significant aortic valve stenosis (valve area &lt; 1cm2)&#xD;
&#xD;
          -  Age &gt; 75 (years Aarhus University Hospital, Skejby)&#xD;
&#xD;
          -  Age &gt; 80 years (other participating centres)&#xD;
&#xD;
          -  Operable by conventional surgery AND transapical stent valve implantation&#xD;
&#xD;
          -  Expected survival &gt; 1 year following successful treatment&#xD;
&#xD;
          -  Accept of participation and in follow-up investigations after adequate information&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coronary artery disease requiring PCI or CABG&#xD;
&#xD;
          -  Earlier cardiac surgery&#xD;
&#xD;
          -  Myocardial infarction within 24 hours&#xD;
&#xD;
          -  Kidney failure requiring any dialysis&#xD;
&#xD;
          -  Ongoing infection&#xD;
&#xD;
          -  Acute surgery&#xD;
&#xD;
          -  Allergy to ASA or Clopidogrel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evald H Christiansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skejby Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus N</city>
        <state>Region Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>September 25, 2009</study_first_submitted>
  <study_first_submitted_qc>September 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Evald Hoej Christiansen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>Stent Valve</keyword>
  <keyword>Biological Aortic Valve Prosthesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

